Research article
Active immunization to tumor necrosis factor-α is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis
-
* Corresponding author: Marie-Christophe Boissier boissier@univ-paris13.fr
1 EA4222, Li2P, University of Paris 13, 74 rue Marcel Cachin, 93000, Bobigny, France
2 Rheumatology Department, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), 125 rue de Stalingrad, 93000, Bobigny, France
3 Neovacs SA, 3-4 impasse Reille, 75014, Paris, France
4 Debiopharm SA, Chemin Messidor 5-7, Case Postale 5911, CH-1002, Lausanne, Switzerland
Arthritis Research & Therapy 2009, 11:R195 doi:10.1186/ar2897
Published: 23 December 2009Additional files
Additional file 1:
TNF-K immunization protocol scheme. Long-term follow -up of the experiment is represented by horizontal arrow with time expressed in week (from week 9, w9, to week 45, w45). Slashes represent discontinuation of time. A- Control group treated with PBS/ISA-51; B- TNF-K group; C- Intermittent infliximab group. The follow-up for each group (PBS, TNF-K and infliximab) is represented by a larger black line, with vertical black arrows at each time where treatment was given. IP injections, intraperitoneal injections.
Format: PDF Size: 6KB Download file
This file can be viewed with: Adobe Acrobat Reader
Additional file 2:
Evolution of neutralizing anti-hTNF-α antibody titers during time, in TTg mice immunized with TNF-K. 36 TTg mice were immunized with TNFK at days 0, 7 and 28. Bleeding was done every month from day 38 post primo-injection to sacrifice. Results are expressed as mean ± SEM of all the sera of all the 36 immunized mice.
Format: PDF Size: 12KB Download file
This file can be viewed with: Adobe Acrobat Reader